[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606561":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":48,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":81,"whyStopped":20,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin D","EXPERIMENTAL","Participants who have IBD (UC or CD) will receive Vitamin D3 and will take a 2000 IU pill daily for 12 months.",[13],"Dietary Supplement: Vitamin D3 (Cholecalciferol)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIETARY_SUPPLEMENT","Vitamin D3 (Cholecalciferol)","2000 IU of Vitamin D daily (1 pill)",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Terry Ponich, MD","Victoria Hospital - London Health Sciences Centre","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Samantha C Hess, BSc Honours","CONTACT","226-377-4557","sam.hess@lhsc.on.ca",[33],{"facility":24,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"London","Ontario","N6A 5A5","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-81.23304,42.98339,{"lat":43,"lon":42},[46,47],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Terry Ponich","Gastroenterology Team Clinician - Victoria Hospital (LHSC)","100606561","phase-1-the-prospective-improved-vitamin-d-study-for-inflammatory-bowel-disease-patients-100606561",false,"NCT07177157","The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients","The Prospective Improved Vitamin D Study for IBD Patients Part 2 (The PIVD Study Part 2)","PIVD","Inclusion Criteria:\n\n1. Adults Aged 18-85\n2. Diagnosis of IBD (Ulcerative Colitis or Crohn's Disease) within the patient's records based on standard clinical, endoscopic, and radiologic criteria.\n3. Patients within outpatient gastroenterology clinics at Victoria Hospital and St. Joseph's Hospital with follow-up appointments within the next 2 years (ongoing IBD care).\n4. Participants must have the ability to read, comprehend, and voluntarily provide informed consent without assistance.\n\nExclusion Criteria:\n\n1. Those who do not meet the inclusion criteria.\n2. Those with any concurrent diagnosis of disease that may affect calcium or Vitamin D metabolism (i.e., rheumatoid arthritis or other inflammatory joint disease, thyroid disease, parathyroid disease, primary bone disease, granulomatous disease, sarcoidosis, lymphoma).\n3. Those with either renal dysfunction (serum creatinine \\>0.150 mmol\u002FL) or receiving dialysis were excluded, patients with chronic liver disease, and hypercalcemia (\\>2.65mmol\u002FL).\n4. Those using oral corticosteroids for the management of any disease other than IBD.\n5. Those with a history of Vitamin D or calcium supplementation within 6 months prior to the trial.\n6. Those who were seen once by the gastroenterology team but never followed up (no ongoing IBD care).","ALL","18 Years","85 Years",{"count":64,"type":65},150,"ESTIMATED","INTERVENTIONAL",[68],"PHASE1","The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are:\n\n1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period?\n2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients?\n3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period?\n4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period?\n5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients?\n6. Is 2,000 IU\u002FDay an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients?\n\nParticipants will:\n\n* Take 2000 IU of Vitamin D every day for the next 12 months\n* Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up",[71,72,73],"Ulcerative Colitis (UC)","IBD (Inflammatory Bowel Disease)","Crohn Disease (CD)",[75,76,77,78,79,80,73],"vitamin D","Inflammatory Bowel Disease","IBD","Ulcerative Colitis","Bone Health","Immune Modulation","NOT_YET_RECRUITING","2025-09-12",{"date":84,"type":85},"2025-09-16","ACTUAL",{"date":87,"type":65},"2025-10",{"date":89,"type":65},"2027-03",{"name":50,"class":6},1]